Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant
Authors:
- Irene CassanitiICIrene Cassaniti
- Federica BergamiFBFederica Bergami
- Francesca ArenaFAFrancesca Arena
- Jose Camilla SammartinoJSJose Camilla Sammartino
- Alessandro FerrariAFAlessandro Ferrari
- Federica ZavaglioFZFederica Zavaglio
- Irene CurtiICIrene Curti
- Elena PercivalleEPElena Percivalle
- Federica MeloniFMFederica Meloni
- Laura PandolfiLPLaura Pandolfi
- Carlo PellegriniCPCarlo Pellegrini
- Annalisa TurcoATAnnalisa Turco
Open Access
- 18 December 2021
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2622
Abstract
The immunogenicity of severe acute respiratory syndrome 2 virus (SARS-CoV-2) vaccines in immunocompromised patients remains to be further explored. Here, we evaluated the immunogenicity elicited by complete vaccination with BNT162b2 vaccine in solid organ transplant recipients (SOTRs). A cohort of 110 SOTRs from Northern Italy were vaccinated with two doses of BNT162b2 mRNA vaccine and prospectively monitored at baseline and after 42 days. Both SARS-CoV-2 naïve and recovered subjects were included. Humoral response elicited by vaccination, including SARS-CoV-2 neutralizing antibodies (SARS-CoV-2 NT Abs), was evaluated; additionally, ex-vivo ELISpot assay was performed for the quantification of Spike-specific T-cell response. Results were compared with those obtained in a cohort of healthy subjects. In a subset of patients, humoral and T-cell responses against delta variant were also evaluated. Less than 20% of transplanted subjects developed a positive humoral and cell-mediated response after complete vaccination schedule. Overall, median levels of immune response elicited by vaccination were significantly lower with respect to controls in SARS-CoV-2 naïve transplant, but not in SARS-CoV-2 recovered transplanted patients. Additionally, a significant impairment of both humoral and cell-mediated response was observed in mycophenolate-treated patients. Positive delta-SARS-CoV-2 NT Abs levels were detected in almost all the SARS-CoV-2 recovered subjects but not in previously uninfected patients. Our study supports previous observations of a low level of seroconversion after vaccination in transplanted patients.Keywords
Funding Information
- Fondazione Cariplo (2020-1374)
- Ministero della Salute (Ricerca Corrente 8073621, Ricerca Finalizzata 2020-12371760)
- European Commission (101003650-ATAC)
This publication has 36 references indexed in Scilit:
- An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplantsKidney International, 2020
- Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant RecipientsTransplantation, 2020
- Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experienceAmerican Journal of Transplantation, 2020
- Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020Eurosurveillance, 2020
- Covid-19 and Kidney TransplantationNew England Journal of Medicine, 2020
- Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, ItalyKidney International Reports, 2020
- The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantationInternational Urology and Nephrology, 2012
- Maintenance immunosuppressive therapy with everolimus preserves humoral immune responsesKidney International, 2010
- Monoclonal antibodies versus reverse transcription‐PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospitalJournal of Medical Virology, 2004
- Suppression of the humoral immune response by mycophenolate mofetilNephrology Dialysis Transplantation, 1998